Phase 3 results are needed No cardiovascular outcomes data available The biased signaling mechanism, while promising, needs long-term validation Exact molecular structure has not been publicly disclosed Phase 3 trials are planned but not yet enrolled Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity , published in Cell Metabolism (Roche/Genentech/Carmot Therapeutics investigators, 2025
Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis
L-theanine is well-known for its ability to promote relaxation without any sedative effects or risk of chemical dependency, making it a perfect addition to a sleep aid designed for everyday use
The FDA's adverse event database documented more than 990 reports linked to compounded semaglutide and more than 730 linked to compounded tirzepatide as of May 31, 2026, per publicly available FDA safety communications
If a food isnt sitting well with you, even if its nutrient-dense, you dont have to include it in your diet
